Peritoneal Metastases from Malignant Mesothelioma

Claire Yue Li; H Richard Alexander Jr

doi:10.1016/j.soc.2018.02.010

Peritoneal Metastases from Malignant Mesothelioma

Surg Oncol Clin N Am. 2018 Jul;27(3):539-549. doi: 10.1016/j.soc.2018.02.010.

Authors

Claire Yue Li¹, H Richard Alexander Jr²

Affiliations

¹ Department of Surgery, New York Presbyterian Hospital, 170 William Street, New York, NY 10038, USA.
² Rutgers Cancer Institute of New Jersey, Department of Surgery, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA. Electronic address: richard.alexander@rutgers.edu.

PMID: 29935688
DOI: 10.1016/j.soc.2018.02.010

Abstract

Diffuse malignant peritoneal mesothelioma (MPM) is a rare cancer that is ultimately fatal in almost all afflicted individuals. Morbidity and mortality from MPM is due to its propensity to progress locoregionally within the abdominal cavity. Patients with MPM most commonly present with nonspecific abdominal symptoms that usually lead to diagnosis when the condition is relatively advanced. MPM is considered a chemotherapy-resistant malignancy.

Keywords: Diffuse malignant peritoneal mesothelioma; Early postoperative intraperitoneal chemotherapy; Hyperthermic intraoperative peritoneal chemotherapy; Operative cytoreduction; Peritoneal metastases.

Publication types

Review

MeSH terms

Combined Modality Therapy
Humans
Lung Neoplasms / pathology*
Lung Neoplasms / therapy*
Mesothelioma / pathology*
Mesothelioma / therapy*
Mesothelioma, Malignant
Peritoneal Neoplasms / secondary*
Peritoneal Neoplasms / therapy*
Treatment Outcome